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Summary
Plant alkaloids exhibit a diverse array of structures
and pharmaceutical activities, though metabolic engi-
neering efforts in these eukaryotic pathways have
been limited. Strictosidine synthase (STR) is the first
committed step in the biosynthesis of over two thou-
sand terpene indole alkaloids. We describe a rational
redesign of the STR binding pocket to selectively
accommodate secologanin substrate analogs. The
mutant is selective for a substrate that can be chemo-
selectively derivatized. Evidence that this substrate
can be processed by later steps of the terpene indole
alkaloid pathway is provided. The work demonstrates
that the central enzyme of this alkaloid pathway can be
redesigned and that the pathway can turn over the un-
natural intermediate that is generated. Modulation of
the substrate specificity of enzymes of this complex
pathway is therefore likely to enable metabolic engi-
neering efforts of these alkaloids.
Introduction
Strictosidine synthase (STR) catalyzes a Pictet-Spen-
gler reaction [1] between secologanin 1 and tryptamine
2 (Figure 1A) [2–4]. The resulting product, strictosidine
3, is a common biosynthetic precursor for more than
two thousand terpene indole alkaloids (TIAs) [5–8]. The
TIAs are a diverse, structurally complex class of alka-
loids with important biological activities, including,
most notably, the anticancer agents vinblastine and
vincristine [9].
Redesigning the substrate specificity of this central
enzyme is an important step toward re-engineering the
TIA pathway to produce ‘‘unnatural’’ natural products
with novel or improved biological properties. Although
STR can accommodate certain analogs of tryptamine
and secologanin [10, 11], it would be desirable if the sub-
strate selectivity for this enzyme could be expanded, or
if the enzyme could be engineered to be selective for
unnatural substrates. Here we describe how the STR
binding pocket can be mutated to selectively accommo-
date secologanin substrate analogs. Specifically, the
binding pocket was altered to selectively accommodate
a substrate equipped with a chemoselective functional
group.
*Correspondence: soc@mit.edu
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Results and Discussion
Secologanin is a key substrate in the terpene indole
alkaloid biosynthetic pathway and may be the rate-limit-
ing substrate in vivo [12]. The rearrangement of the
densely functionalized secologanin molecule is res-
ponsible for the diversity of alkaloid structures [13–15].
Secologanin has also been used as an enantiomeric
template to chemically synthesize alkaloid natural
products [16, 17].
Secologanin analogs 4–8 modified at the methyl ester
(R1) and vinyl (R2) positions [18] were assayed with a fam-
ily of STR (C. roseus) mutants (Figures 2A and 2B). STR
mutants were designed based on both sequence homol-
ogy among STR homologs and the recently reported
crystal structure of STR from R. serpentina (Figure 2A)
[11]. The mutant enzymes were screened with substrate
analogs 4–8 under competitive assay conditions con-
taining saturating concentrations of tryptamine (2 mM)
and a 1:1 mixture of secologanin (2.5 mM) and secologa-
nin analog (2.5 mM). Product ratios and the relative initial
rates of product formed under these competitive assay
conditions were compared by integration of product
peaks by HPLC at 280 nm.
The most favorable increase in selectivity was ob-
served with the pentynyl secologanin derivative 4 and
mutant D177A. The rate of wild-type strictosidine 3 to un-
natural product formation 9 (Figure 1B) was 5.4:1 in favor
of the wild-type product. However, the ratio changed to
0.66:1 strictosidine 3:strictosidine analog 9 with the
D177A mutation, indicating that the mutant preferentially
turns over the bulkier, more hydrophobic substrate ana-
log (Figure 3). Surprisingly, the somewhat shorter alkyne
analog 5 displayed much lower activity than secologanin
1 in this competition assay (relative rate ratio was 75:1
strictosidine:strictosidine analog) with STR, though mu-
tation to D177A did improve the turnover of this substrate
in the competition assay (relative rate ratio was 46:1
strictosidine:strictosidine analog). D177A also exhibited
enhanced specificity for the more hydrophilic analog 6
(Figure 2B), showing a ratio of 1.7:1 strictosidine 3:stric-
tosidine analog compared to 8.8:1 for wild-type in the
competition assay. The specificity for analog 4 was also
moderately increased by the mutation of D177 to G (a
ratio of 1.5:1 strictosidine 3 to analog 9).
High-resolution mass spectrometry analysis con-
firmed the identity of all enzymatic products. To further
validate the identity and stereochemistry of the enzy-
matic product 9, an authentic standard was chemically
synthesized. The stereochemistry of the standard was
validated by NMR data that showed a chemical shift at
3.09 ppm with vicinal coupling constants of J15, 14S =
3.9 Hz and J5, 14R = 11.0 Hz that was assigned to H-15
(Figure 1A), suggesting that C-15 is in the S configura-
tion, as in strictosidine [19]. A signal at 4.33 ppm (J3, 14S =
3.1 Hz and J3, 14R = 10.4 Hz) assigned to H-3 (Figure 1A)
is also in agreement with the strictosidine stereoisomer;
the signal for H-3 of the diastereomer vincoside (C-15 =R
stereoisomer) should appear further down field and
J3, 14S > J3, 14R [19, 20]. Strictosidine and vincoside
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(A) Reaction catalyzed by strictosidine synthase (STR).
(B) Reaction of D177A mutant and chemoselective derivatization.analogs are readily separable by HPLC, and since this
standard displayed the identical HPLC retention time
as the enzymatic product, we conclude that the mutated
enzyme retains same stereoselectivity as wild-type STR.
The crystal structure of STR [11] validates that D177 is
proximal to the methyl ester of secologanin (Figure 4).
When compound 4 is modeled into the secologanin-
binding pocket, the pentynyl group contacts D177;
mutating the aspartate residue to alanine presumably
creates a larger pocket to accommodate the pentynyl
group. Steady-state kinetic analysis with 4 revealed
that the Km of D177A (169.46 30.0 mM) isw2-fold lower
than the Km with STR (312.6 6 15.7 mM). The Vmax value
for D177A with 4 (6 3 1025 6 0.22 mmol/min) is similar
to that of wild-type STR (5 3 1025 6 0.05 mmol/min).
Therefore, the mutation doubled the catalytic efficiency
(Vmax/Km) of the enzyme with 4.
When W153, a residue also proximal to the methyl
ester of secologanin, was mutated to phenylalanine, an
increased selectivity favoring the natural substrate
secologanin 1 compared to analog 4 was observed(11:1 strictosidine 3:analog 9). W153H and W153G
mutants displayed a ratio of 2.7:1 and 2.2:1. The phenyl-
alanine side chain may disrupt the local structure to favor
the smaller methyl ester. However, all W153 mutants ex-
hibited low activity relative to the wild-type enzyme with
both natural and nonnatural substrates (Figure S1, see
the Supplemental Data available with this article online),
thus we hesitate to provide a conclusive structural expla-
nation for this observation. Additionally, the propargyl
functionality of analog 5 is more rigid than the pentynyl
ester 4 and may disrupt the local environment at W153,
accounting for the reduced catalytic efficiency of sub-
strate 5 with both STR and D177A (Figure S2). The longer,
more flexible pentynyl ester of 4 may avoid perturbing
the local environment around W153.
Although a single point mutation could switch the
selectivity of STR for the methyl ester analogs, secolo-
ganin analogs modified at the vinyl position were not
accepted with any point mutations tested (7–8; Fig-
ure 2B) (data not shown). The vinyl group faces into
the interior of the enzyme and appears to be more tightlyFigure 2. Mutations of Strictosidine Synthase and Secologanin Substrate Analogs
(A) Residues mutated in the secologanin binding pocket. C. roseus amino acid numbering is used.
(B) Secologanin substrate analogs.
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Yield 3 and 9
[M+H]+ of 9 expected: 583.2656, found:
583.2639.packed by surrounding residues. More extensive pro-
tein mutations will be required to accommodate these
substrates.
Substrate analog 4 and the resulting enzymatic prod-
uct 9 contain a terminal alkyne that can be chemoselec-
tively modified with an azide derivative under aqueous
conditions using copper-catalyzed cycloaddition, or
click chemistry [21]. The copper-(I)-catalyzed triazole
formation from azides and terminal acetylenes is a pow-
erful reaction, due to its reliability, its specificity, and the
compatibility of the reactants with aqueous reaction
conditions [21]. This mutant enzyme facilitates introduc-
tion of an orthogonal chemical group that will allow
derivatization of the product.
To demonstrate that the enzymatic product could in
fact be derivatized, we used copper-catalyzed click
chemistry to add an azido-derivatized biotin to the ter-
minal alkyne of the strictosidine analog 9 (Figure 1B).
The azide biotin-labeling reagent 10 was prepared
from commercially available biotin amine via the diazo
transfer reaction [22] and then incubated with the pen-
tynyl-strictosidine 9 derivative in the presence of copper
sulfate and ascorbic acid in water to yield 11 in highyields via the copper-catalyzed 1,3-dipolar cycloaddi-
tion (Figure 1B; Supplemental Data).
To our knowledge, this is the first example of modifica-
tion of the substrate specificity of an enzyme in this
pathway and the first example of re-engineering of a
‘‘Pictet-Spenglerase.’’ Modulating the substrate speci-
ficity of the biosynthetic enzymes constitutes an essen-
tial step forward for metabolic engineering efforts in the
TIA pathway. To our knowledge, there is no available lit-
erature precedence that would indicate that the later
steps of this plant pathway can turn over alternative
substrates. However, preliminary data showed that
secologanin analog 4 was incorporated into the hetero-
yohimbine TIA biosynthetic pathway [5] when 4 was
incubated with C. roseus hairy root cell cultures [23].
High-resolution mass spectrometry indicated that the
cell cultures produced a new compound with the ex-
pected molecular weight of a pentynyl serpentine analog
([M]+ expected: 401.1865, found: 401.1860). This com-
pound was not observed in controls cultured in the
absence of substrate 4, suggesting that the formation
of the new product is strictly dependent on the presence
of the ‘‘unnatural’’ substrate (Figure S3).Figure 4. Crystal Structure of Strictosidine
Synthase with Secologanin
The ester of secologanin (R1) is highlighted
with an arrow. Glutamine 282 is a methionine
residue in the R. serpentina enzyme. Struc-
ture taken from PDB file 2FPC [11].
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Utilizing the biosynthetic machinery of C. roseus to
make alkaloid analogs is an attractive strategy to
obtain novel ‘‘natural’’ products. Understanding the
substrate specificity of the biosynthetic enzymes and
re-engineering them to manipulate their activity and
selectivity is key to realizing this goal. We have demon-
strated that the selectivity of STR, the central enzyme
of this alkaloid pathway, can be tuned with a single
point mutation. Based on structural information, we
were able to modulate the enzyme activity to accept
secologanin analogs containing a chemical tag that
can be selectively derivatized at a later stage via
copper-catalyzed cycloaddition. Moreover, we show
evidence that this analog can be processed by later
steps of the terpene indole alkaloid pathway. Notably,
the biological activity of natural products is often
improved by modifications to the structures. For exam-
ple, a fluorinated semisynthetic derivative of the TIA
vinblastine is showing promise in clinical trials [24].
The terpene indole alkaloid biosynthetic pathway
may provide a convenient, economical means of ob-
taining additional derivatives of terpene indole alka-
loids that show improved biological activity.
Experimental Procedures
Mutant Construction, Protein Expression, and Purification
Strictosidine synthase was expressed and purified as previously de-
scribed [10]. Briefly, enzymes were expressed in E. coli BL21(DE3)
and subjected to a one-step affinity purification step by amylose
column (New England Biolabs). The Stratagene QuikChange Site-
Directed Mutagenesis Kit was used to incorporate the desired
mutations into the expression plasmid. Mutagenesis primers were
synthesized by Integrated DNA Technologies (Table S1). Each
mutant was sequenced to confirm the desired amino acid mutation.
Expression and purification were analyzed by SDS-PAGE. Protein
concentration was determined using Bio-Rad Protein Assay micro-
assay protocol, absorbance at 280 nm, and by scanning densitome-
try of an SDS-PAGE.
Activity Assay for Strictosidine Synthase and Mutants
Strictosidine synthase and mutant activity was measured using
an HPLC assay. Protein (100 nM) was incubated with tryptamine,
secologanin, in 100 mM NaH2PO4 (pH 6.8 at 30
C). An aliquot of
the reaction (20 ml) was directly injected onto the HPLC (Hibar RT
250-4LiCHrosorb) using a 22%–95% acetonitrile/water gradient.
The absorbance of tryptamine and strictosidine was monitored at
280 nm. A standard curve of strictosidine was used to convert
absorbance units to millimoles.
To obtain qualitative activity data, concentrations of 2 mM trypt-
amine and 2.5 mM secologanin were utilized and assayed for four
time points to obtain a linear rate (Figure S1).
Competitive assays contained tryptamine (2 mM) and a 1:1
mixture of secologanin (2.5 mM) and secologanin analog (2.5 mM).
The relative ratios of product formed were compared by integration
of product peaks at 280 nm.
To obtain kinetic values for secologanin analog 4, the tryptamine
concentration was held constant at 2 mM, and reaction rates were
measured at seven secologanin analog concentrations (50 mM to
1.2 mM). 1-Naphthalene-acetic acid (140 mM) was used as an internal
standard to ensure accurate injection volume. The reactions were
quenched with NaOH (2 equiv.). All kinetic assays were performed
in triplicate. Kinetic parameters were obtained using Origin 7.0
software (Origin lab). A negative control performed in the absence
of enzyme ensured that negligible background reaction occurred un-
der the assay conditions. The identity of the alternate product was
validated by mass spectrometry, and coelution with an authentic
standard. A diastereomeric mixture of the authentic standard wassynthesized, and the S diastereomer was purified and characterized
by NMR spectroscopy. This demonstrated that the mutant enzyme
yielded the S stereocenter. For the enzymatic product 9, high-resolu-
tion mass spectrometry yielded m/z 583.2639 [M+H]+ (expected m/z
583.2656 [M+H]+).
General Chemical Methodology
Chemicals were purchased from Aldrich and used without further pu-
rification. All reactions were performed under anhydrous conditions
and monitored by TLC on Kieselgel 60 F254 (EMD). Detection was
carried out by examination under UV light (254 nm) and by charring
with cerium molybdate stain. Flash chromatography was performed
on silica gel (Sorbent Technologies, 60 m, mesh 32–63 mm). Extracts
were concentrated under reduced pressure at <40C. 1H NMR (1D,
2D), and 13C NMR spectra were recorded on a Varian Merc300 MHz
and Varian 500 MHz spectrometers equipped with Sun workstations.
For 1H and 13C NMR spectra recorded in CD3OD, chemical shifts (d)
are given in ppm relative to solvent peaks (1H, d = 3.32; 13C, d =
49.1) as an internal standard. The LC/MS analysis of samples was
performed on a Waters Acquity UPLC system ionized by ESI with
a Micromass LCT Premier TOF Mass Spectrometer as a detector.
The LC was run on a BEH C18, 1.7 mm, 2.1 3 100 mm column. The
capillary and sample cone voltages were 2000 and 100 V. The desol-
vation and source temperatures were 350C and 100C. The cone
and desolvation gas flow rates were 20 and 700 liters/hr. Analysis
was performed with MassLynx 4.1.
Pentynyl 5-Ethenyl-4-(2-Oxoethyl)-6-[3,4,5-Trihydroxy-6-
(Hydroxymethyl) Oxan-2-yl]oxy-5,6-Dihydro-4H-Pyran-3-
Carboxylate (4)
Secologanin (50 mg, 0.13 mmol) was dissolved in 4-pentyn-1-ol
(4 ml), sodium bicarbonate (3 equiv.) was added, and the mixture was
stirred at 90C for 4 hr. Completion of the reaction was determined
by MS (ESI). The reaction was filtered and concentrated to a minimum
volume, and the crude product was subjected to flash column chro-
matography (CH2Cl2/MeOH, 9/1), followed by C18 chromatography
(MeOH/H2O, 8/2) and preparative HPLC (H2O [0.1% TFA]/MeCN,
gradient 20%–50% MeCN over 20 min) to give the desired com-
pound. 1H NMR (CD3OD, 500 MHz): 9.68 (s, 1H), 7.48 (s, 1H), 5.77–
5.66 (m, 1H), 5.56 (d, 1H, J5.8), 5.40 (dd, 1H, J5.8, 10.6), 5.30 (t, 1H,
J10.9), 4.79 (d, 1H, J7.7), 4.70 (m, 1H), 4.22 (m, 1H), 3.90 (dd, 1H,
J2.1, 12.3), 3.66 (m, 1H), 3.60–3.48 (m, 1H), 3.45 (m, 1H), 3.40–3.18
(m, 2H), 3.04 (m, 1H), 2.76 (m, 1H), 2.38–2.24 (m, 2H), 2.10–1.98 (m,
1H), 1.88 (s, 1H), 1.74 (m, 1H), 1.68–1.58 (m, 2H). ESI(C21H28O10):
calculated m/z 441.2 [M+H]+, found m/z 441.2 [M+H]+.
Strictosidine Pentynyl Ester Analog (9)
Tryptamine hydrochloride (2.04 mg, 12.8 mmol) and pentynyl secolo-
ganin (2.8 mg, 6.4 mmol) were dissolved in an aqueous solution of
maleic acid (0.5 ml, 100 mM [pH = 2]), and the reaction was stirred
at ambient temperature overnight. Upon disappearance of the start-
ing materials, the crude mixture was subjected to preparative HPLC
purification on a Grace vydac column (C18 monomeric, 100A, H2O
[0.1% TFA]/MeCN, gradient 20%–60% MeCN over 20 min, RT, 14
min) to give 1 mg (30%) of the desired stereoisomer. 1H NMR
(CD3OD, 500 MHz): d7.58 (s, 1H, H-17), 7.48 (d, 1H, J9,10 7.8, H-9),
7.32 (d, 1H, J12,11 8.5, H-12), 7.15 (dd, 1H, J11,10 7.0, H-11), 7.06
(dd, 1H, H-11), 6.01 (m, 1H, H-19), 5.86 (d, 1H, J21,20 8.9, H-21),
5.38 (dd, 1H, J18z,19 17.4, H-18Z), 5.38 (dd, 1H, J18E,19 17.4,
H-18E), 4.81 (d, 1H, J10,20 7.6, H-10), 4.33 (dd, 1H, J3, 14S 3.1, J3,
14R 10.4, H-3), 4.19 (m, 1H, H-23b), 4.08 (m, 1H, H-23a), 4.01 (dd,
1H, J6a0,6b0 2.1, J6a0,50 2.8, H-6a0), 3.65 (dd, 1H, J6b0,50 11.6,
H-6b0), 3.50–3.20 (m, 4H, H-20, H-30, H-40, H-50), 3.47 (m, 1H, H-5b),
3.18 (m, 1H, H-5a), 3.09 (dd, 1H, J15, 14S 3.9, J5 14R 11.0, H-15),
2.83 (m, 1H, H-6b), 2.75 (m, 1H, H-6a), 2.21 (dd, 1H, J14R, 14S 13.0,
H-14S), 1.95 (dd, 1H, H-14R), 2.10 (m, 2H, H-25), 1.74 (m, 1H, H-27),
1.61 (m, 2H, H-24). ESI (C31H38N2O9): calculated m/z 583.2656
[M+H]+, found m/z 583.2639 [M+H]+.
Supplemental Data
Supplemental data describing evaluation of secologanin concentra-
tion, synthesis of biotin azide, and synthesis of biotinylated strictosi-
dine are available at http://www.chembiol.com/cgi/content/full/
13/11/1137/DC1/.
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